Search results
Dec 10, 2021 · Chronic graft-versus-host disease (GVHD) is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. Symptoms and manifestations of chronic GVHD are heterogeneous and pleomorphic, and there are no standard treatments beyond corticosteroids.
While the incidence of cGVHD is lower (20–40%) in children, its incidence rises to 60% as age increases (Baird et al. 2010 ). The pathophysiology of cGVHD is different from aGVHD and mainly characterized by impaired immune tolerance mechanisms affecting innate and adaptive immunity.
- Daniel Wolff, Anita Lawitschka
- 10.1007/978-3-030-02278-5_44
- 2019
- 2019
Jun 7, 2024 · Graft-versus-host disease (GVHD) is a systemic disorder occurring when immune cells from transplanted tissue recognize the recipient's body as foreign and attack its cells. In this context, graft refers to transplanted or donated tissue, while host refers to the recipient's tissues.
- Angel A. Justiz Vaillant, Pranav Modi, Oranus Mohammadi
- 2024/06/07
- 2019
Dec 10, 2021 · A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
Apr 8, 2020 · Acute and chronic graft-versus-host disease (GVHD) are multisystem disorders that are common complications of allogeneic hematopoietic cell transplant (HCT). GVHD occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that ...
Complete response (CR) rates at day 28 were 26%, 60%, 53% and 38% respectively with 9-month overall survival of 47%, 64%, 49% and 47% [ Alousi et al. 2009 ]. Based on these findings, a phase III trial comparing steroid therapy plus MMF with steroid therapy alone was initiated (BMT CTN Study 0802).
People also ask
What is graft versus host disease?
What is graft versus host disease (GVHD)?
What is the clinical grading system for chronic graft-versus-host disease (GVHD)?
What is chronic graft-versus-host disease (GVHD)?
Systemic therapy: treatment with oral or intravenous (IV) steroids. treatment with ibrutinib (Imbruvica®), a drug that affects your immune cells. treatment with ruxolitinib (Jakafi®), a drug that is anti-inflammatory and suppresses your immune system.
